Atopic dermatitis and skin diseaseGlobal variations in prevalence of eczema symptoms in children from ISAAC Phase Three
Section snippets
Methods
ISAAC Phase Three used the same protocol, framework for registration of participating centers, and sampling as ISAAC Phase One.12, 14 Briefly, 2 age groups (6-7 and 13-14 years old) were chosen from a random sample of schools from defined geographical areas. A simple questionnaire with questions related to symptoms of wheezing, rhinoconjunctivitis, and eczema was completed by parents of the children and by the adolescents. Only the eczema data are reported and discussed here; the asthma and
Results
For the age group 6 to 7 years, data from 421,543 participants in 165 centers (65 countries), and for the age group 13 to 14 years, data for 814,837 participants in 242 centers (98 countries) were submitted to the ISAAC International Data Centre for analyses. Adherence to the ISAAC Protocol was assessed, and centers that had not included the eczema questionnaire or had serious deviations from protocol were excluded from the analyses (22 centers from 17 countries with 35,690 participants for the
Main findings
This is the largest study to date that estimates the prevalence of eczema symptoms in children and adolescents, and it contains over twice as much data and increased global coverage when compared with ISAAC Phase One. For the age group 6 to 7 years, Phase Three includes a further 87 centers from 27 new countries, and for the age group 13 to 14 years, a further 133 centers from 43 new countries. The increased coverage provides valuable new insights into the global variation of symptoms of
References (40)
- et al.
Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood
J Allergy Clin Immunol
(1999) - et al.
[Prevalence of atopic dermatitis in schoolchildren from Cartagena (Spain) and relationship with sex and pollution]
An Pediatr (Barc)
(2004) - et al.
Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6–7 years: analysis from Phase Three of the ISAAC programme
Lancet
(2008) - et al.
Antibiotic use in infancy and symptoms of asthma, rhinoconjunctivitis and eczema in 6-7 year olds: ISAAC Phase Three
J Allergy Clin Immunol
(2009) - et al.
The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis, I: derivation of a minimum set of discriminators for atopic dermatitis
Br J Dermatol
(1994) - et al.
The natural history of childhood eczema: observations from the British 1958 birth cohort study
Br J Dermatol
(1998) - et al.
The role of atopic sensitization in flexural eczema: findings from the International Study of Asthma and Allergies in Childhood Phase Two
J Allergy Clin Immunol
(2008) Diagnostic criteria for atopic dermatitis: where do we go from here? [letter; comment]
Arch Dermatol
(1999)- et al.
The socioeconomic impact of atopic dermatitis in the United States: a systematic review
Pediatr Dermatol
(2008) - et al.
Assessment of outcomes and parental effect on Quality-of-Life endpoints in the management of atopic dermatitis
Manag Care Interface
(2007)
The burden of atopic dermatitis: impact on the patient, family, and society
Pediatr Dermatol
Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema
Int J Clin Pract
Sleep disruptions in parents of children and adolescents with chronic illnesses: prevalence, causes, and consequences
J Pediatr Psychol
Atopic dermatitis: impact on the quality of life of patients and their partners
Dermatology
The International Study of Asthma and Allergies in Childhood (ISAAC)
Clin Exp Allergy
Is eczema really on the increase worldwide?
J Allergy Clin Immunol
The International Study of Asthma and Allergies in Childhood (ISAAC): Phase Three rationale and methods
Int J Tuberc Lung Dis
Global map of the prevalence of symptoms of rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three
Allergy
Global variation in the prevalence and severity of asthma symptoms: Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC)
Thorax
Translation of questions: the International Study of Asthma and Allergies in Childhood (ISAAC) experience
Int J Tuberc Lung Dis
Cited by (717)
Incident Asthma, Asthma Exacerbations, and Asthma-Related Hospitalizations in Patients With Atopic Dermatitis
2024, Journal of Allergy and Clinical Immunology: In PracticeThe influence of modern living conditions on the human microbiome and potential therapeutic opportunities for allergy prevention
2024, World Allergy Organization JournalBehavioral disorders in children and adolescents with atopic dermatitis
2024, Jornal de Pediatria
Currently the main source of funding for the ISAAC International Data Centre (IIDC) is the BUPA Foundation. Many New Zealand funding bodies have contributed support for the IIDC during the periods of fieldwork and data compilation (the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the NZ Lottery Board, and Astra Zeneca New Zealand). Glaxo Wellcome International Medical Affairs supported the regional coordination for Phase Three and the IIDC.
Disclosure of potential conflict of interest: T. O. Clayton and M. I. Asher have received research support from the BUPA Foundation (UK). C. F. Robertson has received research support from the National Health Medical Research Council. J. A. Odhiambo and H. C. Williams have declared that they have no conflict of interest.
- ∗
Members listed in this article's Appendix E1 in the Online Repository at www.jacionline.org.